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Comparative genomic studies have identiﬁed several Mycobacterium tuberculosis-speciﬁc genomic regions of diﬀerence (RDs)
which are absent in the vaccine strains of Mycobacterium bovis BCG and which may be useful in the speciﬁc diagnosis of
tuberculosis (TB). In this study, all encoded proteins from DNA segment RD5 of Mycobacterium tuberculosis, that is, Rv3117–
Rv3121, were recombined and evaluated by enzyme-linked immunosorbent assays for antibody reactivity with sera from HIV-
negative pulmonary TB patients (n = 60) and healthy controls (n = 32). The results identiﬁed two immunodominant antigens,
that is, Rv3117 and Rv3120, both of which revealed a statistically signiﬁcant antigenic distinction between healthy controls and TB
patients(P<0.05).Incomparisonwiththewell-knownearly-secretedantigentarget6kDa(ESAT-6)(sensitivity21.7%,speciﬁcity
90.6%), the higher detection sensitivity and higher speciﬁcity were achieved (Rv3117: sensitivity 25%, speciﬁcity 96.9%; Rv3120:
sensitivity 31.7%, speciﬁcity 96.9%). Thus, the results highlight the immunosensitive and immunospeciﬁc nature of Rv3117 and
Rv3120 and indicate promise for their use in the serodiagnosis of TB.
1.Introduction
Tuberculosis (TB) is an infectious disease caused by Myco-
bacterium tuberculosis (M. tuberculosis) and is still a serious
global health care problem. In 2010, there were 8.8 million
incident cases of TB with 1.45 million deaths [1]. Over
the past two decades, drug-resistant TB [2]a n dT B / H I V
coinfection[3]furtherthreatenedtounderminetuberculosis
control. Until now, there is no simple, rapid, sensitive, and
speciﬁc test that can be used for diagnosis of tuberculosis.
The gold standard for TB diagnosis is the demonstration
of M. tuberculosis in various body ﬂuids. However, this is
often impossible due to the paucibacillary nature of the ill-
ness in some cases, especially in smear-negative TB patients.
Currently, diagnosis of TB relies mainly on clinical exami-
nation and radiographical ﬁndings and is further conﬁrmed
by bacterial culture and acid-fast bacilli (AFB) smear
microscopy [4]. However, it requires long time, and it is
also not very sensitive; sometimes other mycobacteria found
in sputum [5] may decrease the speciﬁcity. In recent years
several rapid diagnostic techniques have been investigated to
determine their ability to improve the diagnosis of TB, such
as polymerase chain reaction (PCR) and other methods for
amplifying DNA and RNA, though they permit the diagnosis
of tuberculosis in as little as several hours, their applicability
is limited by low sensitivity, high level of training required,
and high cost [6, 7].2 Clinical and Developmental Immunology
In search for rapid and cost-eﬀective diagnostic methods
for TB, immunodiagnosis is considered an attractive option,
which uses the speciﬁc humoral and cellular immune
responses of the host to infer the presence of infection or
disease. Recently, the antigen-speciﬁc ex vivo induction of
interferon gamma (IFN-γ) had been used to detect infection
with M. tuberculosis. However, the IFN-γ release assay could
not diﬀerentiate the latent tuberculosis infection and active
tuberculosis eﬃciently and cannot be recommended for
the diagnosis of tuberculosis in developing countries, as
large proportions of the populations in such countries are
likely to harbor latent infection with M. tuberculosis [8–
10]. Historically speaking, serology for the diagnosis of TB
has been explored since 1898, when crude cell preparations
containingcarbohydrates,lipids,andproteinsfromM.tuber-
culosis or M. bovis BCG were used as antigen preparations
showing high sensitivity but low speciﬁcity [11]. Modern
developments in the puriﬁcation of antigens, generation
of monoclonal antibodies and chromatographic techniques,
have led to a considerable improvement in speciﬁcity [12–
18]. Serology has additional advantages in situations when
the patient is unable to produce adequate sputum or sputum
smear results are negative and TB is extrapulmonary.
Comparative genomic studies have identiﬁed several M.
tuberculosis-speciﬁc genomic regions of diﬀerence (RDs)
which are absent in the avirulent M. bovis Bacille Calmette-
Gu´ erin (BCG) strains [19, 20] and which may be useful in
the speciﬁc diagnosis of TB. For example, ESAT-6, culture
ﬁltrate protein 10kDa (CFP-10) [16, 17], Rv3872 [21],
and Rv3873 [22] from RD1 were identiﬁed as promising
diagnostic antigens. Previous studies had also described a
protein antigen Rv3425, which was encoded by an open
reading frame (ORF) found in RD11 of M. tuberculosis and
had a strong immunogenicity, suggesting it was a potential
candidate for the serodiagnosis of active TB [12, 23]. In
this study, we cloned, expressed, and puriﬁed the RD5-
encoded M. tuberculosis recombinant proteins and evaluated
the immunoreactivity of the target proteins with sera from
HIV-negative pulmonary TB patients and healthy controls,
respectively. We aimed at revealing other serological antigens
to improve serodiagnostic sensitivity for TB.
2.MaterialsandMethods
2.1. Genomic DNA Extraction. M. tuberculosis . H37Rv was
cultured on the Lowenstein-Jensen medium at 37◦Cf o rf o u r
weeks, and the bacteria (2mg) were heat-killed at 95◦Cf o r
1h and then treated with 2mg lysozyme in 1mL TE buﬀer
at 37◦C for 2h. Subsequently, the cells were subjected to 1%
SDSand50μg/mLproteaseKtreatmentsat55◦Cfor2h.The
contained DNA was extracted with phenol and chloroform
and precipitated with ethanol and 3mol/L sodium acetate
(pH 5.2), followed by being dissolved in TE buﬀer and stored
at −20◦C.
2.2. Generation of Recombined RD5-Encoded M. tuberculo-
sis Proteins. The ORFs corresponding to Rv3117, Rv3118,
Rv3119, Rv3120, and Rv3121 were ampliﬁed by PCR from
the genomic DNA of H37Rv, respectively. The primers,
restriction endonucleases used, vectors, and annealing tem-
peratureforthermalcycleampliﬁcationareshowninTable 1.
The PCR products were cloned into N-terminal or C-
terminal His-tagged expression vector pET-21a, pET-32a, or
pET-28b (Novagen, CA, USA) at the restriction sites indi-
cated, and the generated recombinant plasmids were trans-
formed into E. coli BL21 (DE3) pLysS for expression. After
DNA sequencing, individual transformant was cultured
overnight in LB medium containing 50μg/mL kanamycin or
ampicillin, and then the target proteins were induced with
1–50mmol/L isopropyl-b-D-thiogalactopyranoside (IPTG)
for 3h. The recombinant proteins were puriﬁed by immo-
bilized metal aﬃnity chromatography (IMAC) according
to the manufacturer’s protocol (Bio-Rad Laboratories Ltd.,
Shanghai, China). Finally, the recombinant protein purity
and content were assessed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) analysis and
Bradford’s assay using bovine serum albumin (BSA) as the
protein standard [24], respectively.
2.3. Serum Samples. A total of 60 serum samples (n = 60)
from HIV-seronegative active TB patients (age range, 1–
81 years) and 32 serum samples (n = 32) from healthy
control subjects (age range, 20–63 years) were collected from
the Wuxi No. 5 people’s hospital, Jiangsu, China. Active TB
patients were diagnosed as previously [25] and were further
classiﬁed into two groups: (i) smear-positive for acid-fast
bacilli (AFB) and culture-positive pulmonary TB (n = 48)
and (ii) smear-negative culture-positive pulmonary TB (n =
12). All of health controls had not previously suﬀered from
TB and had negative chest X-rays and negative sputum cul-
tureresultsforM.tuberculosis.TwelveofthesewerePPDpos-
itive at the time the serum samples were taken. All patients
had not yet been started with antituberculous chemotherapy
when the serum samples were taken. Sera were stored at
−20◦C.
2.4. Enzyme-Linked Immunosorbent Assays (ELISAs). ELISAs
were performed to check the B-cell immune response
in humans to RD5-encoded M. tuberculosis recombinant
proteins and to the well-known antigen ESAT-6 as our
previous studies [26, 27]. In brief, 96-well polystyrene ﬂat-
bottomed microtiter plates (Costar, USA) were coated with
2–16μg/mL of either RD5-encoded recombinant proteins
or control antigen (Linc-Bio Science Co. LTD, Shanghai,
China), incubated overnight at 4◦C, washed four times with
PBSTwashbuﬀer(Tween-200.05%v/vinPBS),andblocked
with 300μL of blocking buﬀer (bovine serum albumin 2%
w/v in phosphate-buﬀered saline) for 2h at 37◦C. The plates
were then washed four times with PBST wash buﬀer. 50-
fold diluted serums (50μL) in blocking buﬀer were then
added to antigen-coated wells and incubated for 1h at
37◦C. All the samples were tested in duplicate. The plates
were thoroughly washed with PBST and then incubated
with a 1:5000 dilution of anti-human IgG-horseradish
peroxidase (Sigma, Poole, UK) at 37◦C for 1h. Then, the
plates were thoroughly washed again four times, followed
by the addition of 100μL of TMB substrate solution (0.04%
TMB, 0.04% urea peroxide in 0.1M sodium acetate-citricClinical and Developmental Immunology 3
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.4 Clinical and Developmental Immunology
acid buﬀer, pH 4.0). After 10min incubation in the dark at
room temperature, the reaction was stopped by the addition
of 50μLo f2MH 2SO4 to each well, and the values of the
optical density at 450nm (OD450)w e r em e a s u r e dw i t ha
microtiter plate reader (Bio-Rad, USA).
2.5. Statistical Analysis. The ELISA results were analyzed
using cut-oﬀ values equal to the mean OD value for the
healthycontrolserumsamplesplusthreestandarddeviations
(SDs). Any sample exhibiting absorbance above the cut-
oﬀ value was considered to be positive. Sensitivity was
determined by dividing the number of positive cases by the
total number of TB patients. Speciﬁcity was determined by
dividingthenumberofnegativecontrolsbythetotalnumber
of healthy controls. For statistical analysis, the diﬀerences
between diﬀerent TB patients and healthy controls were
calculated by the one-way ANOVA and independent-sample
t-test using the Statistics Package for Social Science 17.0
(SPSSInc.,Chicago,IL,USA),withP<0.05consideredtobe
signiﬁcant. Furthermore, the receiver operation characteris-
tic (ROC) curves of the OD values for antibody responses to
each RD5-encoded recombinant proteins were plotted using
the SPSS17.0 software; the areas of under the curve (AUC)
were calculated, accordingly.
3. Results
3.1. Expression and Puriﬁcation of RD5-Encoded Recombi-
nant Proteins. To evaluate the antigenic ability of RD5-
encoded recombinant proteins, the corresponding genes
were expressed in E. coli BL21 (DE3) PLysS and puriﬁed
as a His-tag fusion protein. The Rv3117, Rv3118, and
Rv3119 recombinant proteins were largely present in the
soluble fraction, and puriﬁcation of them was carried out
under non-denaturing conditions without urea. However,
the Rv3120 and Rv3121 recombinant proteins were largely
present in the insoluble fraction, and therefore the puriﬁ-
cation was carried out under denaturing conditions in the
presence of 6M urea, with a yield of 6.5mg of protein/L of
culture. The overexpressed N-terminal or C-terminal His-
tagged recombinant proteins from RD5 genes were puriﬁed
and conﬁrmed by SDS-PAGE analysis (Figure 1). Then, they
were dialyzed overnight against 20mM Tris-HCl, pH 7.5,
containing 100mM NaCl and glycerol 3% (v/v) and used for
immunoreactivity analyses.
3.2. Immunoreactivity Analyses of RD5-Encoded Recombinant
Proteins. The serum IgG antibody responses to the RD5-
encoded recombinant proteins or ESAT-6 antigen were com-
pared withTB patients and healthycontrolsbyELISAs. Anti-
body responses to the individual protein in TB patients were
analyzed with cut-oﬀ values obtained from 32 healthy indi-
viduals. As shown in Table 2, the sensitivity for detecting
antibody responses to ESAT-6, Rv3117, Rv3118, Rv3119,
Rv3120, and Rv3121 was 21.7%, 25.0%, 11.7%, 11.7%,
31.7%, and 5.0%, respectively, and the speciﬁcity was 90.6%,
96.9%, 90.6%, 96.9%, 96.9%, and 87.5%, respectively. Most
importantly, the sensitivity and speciﬁcity of antibody
detection by Rv3117 and Rv3120 were higher than those of
10
15
25
35
40
55
70
100
130
kDa 1 2 3 4 5 6
Figure 1: SDS-PAGE analysis of puriﬁed RD5-encoded recom-
binant proteins. Lane 1, molecular weight markers (SM0671,
Fermentas, USA). Lane 2–6, puriﬁed Rv3117–Rv3121 recombi-
nant proteins; molecular weight is 48.1kDa, 11.2kDa, 16.9kDa,
38.2kDa, and 45.3kDa, respectively. Proteins were visualized with
Coomassie brilliant blue staining.
antibody detection by ESAT-6 antigen. By combining the
reactivity with recombinant proteins Rv3117 and Rv3120,
a total test sensitivity of 35.0% for active TB patients
was achieved, while good speciﬁcity (96.9%) still remained
(Table 2).
Furthermore, all the OD450 values of antibodies against
RD5-encoded recombinant proteins and ESAT-6 antigen
were used for the generation of ROC curves. The AUC of
ESAT-6antigenis0.680andthoseofRv3117–Rv3121recom-
binant proteins were 0.757, 0.656, 0.632, 0.735, and 0.609,
respectively (ﬁgure not shown), suggesting Rv3117 and
Rv3120 have a better overall diagnostic performance than
any other individual antigen. In the study, all the TB patients
compared with the healthy controls showed statistically sig-
niﬁcant responses against recombinant Rv3117 (P = 0.000),
Rv3118 (P = 0.018), Rv3119 (P = 0.044), and Rv3120 pro-
teins (P = 0.000) other than Rv3121 (P = 0.520) and ESAT-
6( P = 0.079). But antibody responses to EAST-6, Rv3117,
Rv3118, Rv3119, Rv3120, and Rv3121 in the smear-positive
TB patients were no stronger than that in the smear-negative
TB patients (P>0.05) (Figure 2). Meanwhile, the sera
from smear-positive TB also showed a statistically signiﬁcant
response against ESAT-6 antigen (P = 0.047) compared with
the healthy controls. However, the sera form the smear nega-
tive TB patients showed no statistically signiﬁcant response
against ESAT-6 antigen (P = 0.746) compared with the
healthy controls (data not shown). Apparently, characteriza-
tion of antibodies against recombinant proteins Rv3117 and
Rv3120 can eﬀectively distinguish between TB patients and
healthy controls.
4. Discussion
The rapid screening test of active TB remains a serious prob-
lem in clinical practice, although it has been improved byClinical and Developmental Immunology 5
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Figure 2:ThehumoralimmuneresponsesdirectedagainsttheEAST-6antigen(a)andRv3117–Rv3121recombinantproteins((b)–(f))were
comparedamongdiﬀerentcategoriesofpatientsandhealthycontrols.Horizontallinesindicatethemeansandthestandarderrorofthemean
of absorbent value each group. P values are shown above the plots determined by two-tailed one-way ANOVA and independent-samples
t-test.6 Clinical and Developmental Immunology
Table 2: Sensitivities and speciﬁcities for IgG antibodies against RD5-encoded M. tuberculosis proteins.
Sensitivity Sensitivity
Smear-positive
TB (n = 48)
Smear-negative
TB (n = 12)
All TB patients
(n = 60)
BCG-vaccinated
healthy control
(n = 12)
PPD− healthy
control (n = 20)
All healthy
control (n = 32)
ESAT-6a 25.0% (12/48) 8.4% (1/12) 21.7% (13/60) 83.4% (10/12) 95.0% (19/20) 90.6% (29/32)
Rv3117a 25.0% (12/48) 25.0% (3/12) 25.0% (15/60) 91.7% (11/12) 100.0% (20/20) 96.9% (31/32)
Rv3118a 12.5% (6/48) 8.4% (1/12) 11.7% (7/60) 91.7% (11/12) 90.0% (18/20) 90.6% (29/32)
Rv3119a 10.4% (5/48) 16.7% (2/12) 11.7% (7/60) 91.7% (11/12) 100% (20/20) 96.9% (31/32)
Rv3120a 29.2% (14/48) 41.7% (5/12) 31.7% (19/60) 91.7% (11/12) 100.0% (20/20) 96.9% (31/32)
Rv3121a 4.2% (2/48) 8.4% (1/12) 5.0% (3/60) 91.7% (11/12) 85.5% (17/20) 87.5% (28/32)
Rv3117 +
Rv3120b 33.3% (16/48) 41.7% (5/12) 35.0% (21/60) 91.7% (11/12) 100.0% (20/20) 96.9% (31/32)
aThe cut-oﬀ value was calculated from the mean OD value plus three standard deviations (SDs) for healthy controls.
bThe serum tested was determined to be TB positive according to the criteria as follows: any antigen speciﬁcally reacts with serum when the cut-oﬀ value was
calculated from the mean OD plus three standard deviations.
the serodiagnostic methods [23]. These years, comparative
genomic studies using subtractive DNA hybridization [19]
and DNA microarray [20] have identiﬁed several M. tubercu-
losis-speciﬁc genomic regions of diﬀerence, designated RD1
to RD16, which are absent in the vaccine strains of M. bovis
BCG, indicating that the RD-encoded recombinant proteins
may be useful for improving the sensitivity and speciﬁcity
of serodiagnosis TB. Accordingly, RD5 genes are present at
M. tuberculosis but missed from BCG (BCG-Danish, BCG-
pasteur, etc.) [20, 28]. Therefore, in this study, we success-
fully prepared ﬁve RD5-encoded recombinant proteins and
evaluatedbyELISAfortheirdiagnostic potential indetecting
serum antibodies comparison with ESAT-6 antigen which
have been used for the diagnosis of TB [12, 14, 29]i na
population of active TB patients and healthy controls.
Our results revealed that Rv3117 and Rv3120 were
potential candidate antigens for the serodiagnosis of tuber-
culosis. The gene product of open reading frame Rv3117
of M. tuberculosis H37Rv was annotated as encoding a
probable rhodanese-like thiosulfate sulfurtransferase, and it
may be involved in intermediary metabolism and respiration
[30–32]. And Rv3120-encoded protein was annotated as
a conserved hypothetical protein. It was illustrated that
the intactness of the RD5 region might be associated with
increased virulence of the organism [33]. In this study,
the sensitivity of detecting antibody responses to single
recombinant protein Rv3117 or Rv3120 in TB patients and
healthy controls was higher than that to ESAT-6 antigen,
suggesting that they may be valuable for the rapid diagnosis
of TB (Table 2). Notably, we found that no single serum
sample reacted with six proteins tested and no single protein
was recognized by all sera. These ﬁndings further indicated
the heterogeneous antibody responses in tuberculosis [34]
and the importance of the research on TB antibody proﬁle
for improving serodiagnosis of tuberculosis [35, 36], for any
single M. tuberculosis antigen is not enough to be used to
cover the antibody proﬁles of TB patients, but combinations
of antigens may yield improved level of sensitivity, without
aﬀecting speciﬁcity. Since negligible anti-Rv3117 and anti-
Rv3120 responses were obtained in the healthy controls; it
was likely that they were expressed during the course of
M. tuberculosis infection and that they may be associated
with disease manifestation and progression. Our results also
revealed that the speciﬁcity of Rv3117 and Rv3120 in healthy
controls was higher than that of ESAT-6 antigen (Table 2).
They both revealed a statistically signiﬁcant antigenic dis-
tinction between healthy controls and TB patients (P<
0.001) (Figure 2). Therefore, the Rv3117 and Rv3120 recom-
binant proteins may be used for diagnosis of M. tuberculosis
infection.
However,inarecentstudy,atotalof72syntheticpeptides
covering the sequences of ﬁve RD5-encoded proteins had
been tested by ELISAs for antibody reactivity with sera from
HIV-negativepulmonaryTBpatients(n = 100)andM.bovis
BCG-vaccinated healthy subjects (n = 100), but the pooled
peptides were not strongly reactive with TB sera [37]. On the
other hand, by using pools of overlapping synthetic peptides
covering the sequence of RD5-encoded proteins, the CMI
responses have been determined, the INF-γ data showed that
the 11% responses in pulmonary tuberculosis patients and
2% responses in healthy blood donors, and the IL-10 data
showed that the 33% responses in pulmonary tuberculosis
patients and 17% responses in healthy blood donors, as
discussedbyMustafaandAl-Attiyah[38].Furtherstudiesare
in progress to investigate the CMI response to recombinant
protein Rv3117 and Rv3120, with the aim of evaluating its
use in the cellular immunity-based immunodiagnosis of TB.
And it is interesting to speculate on the possible use of the
Rv3117 and Rv3120 proteins with other immunodominant
antigens for vaccine development.
5. Conclusion
In this study, we successfully recombined ﬁve RD5-encoded
proteins and evaluated for their diagnostic potential in
detecting serum antibodies comparison with ESAT-6 antigenClinical and Developmental Immunology 7
with sera from HIV-negative pulmonary TB patients and
healthy control subjects. The results identiﬁed two immun-
odominant antigens, that is, Rv3117 and Rv3120, which
show promise for use in the serodiagnosis of M. tubercu-
losis. They both revealed a statistically signiﬁcant antigenic
distinction between healthy controls and TB patients.
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